Last week, Lion CEO Friedrich von Bolen told the Financial Times Deutschland that the company was in advanced talks for a contract worth more than Lion’s $125 million deal with Bayer.
“At the moment we are in discussions with companies. At least one of the deals could possibly be bigger than the Bayer deal,” von Bolen told the paper.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
